Related Experiment Video
Updated: Dec 15, 2025

Analysis of DNA Double-strand Break DSB Repair in Mammalian Cells
Published on: September 8, 2010
DNA Repair and Prostate Cancer: A Field Ripe for Harvest
Alan H Bryce1, Oliver Sartor2, Johann de Bono3
1Department of Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Abstract:
Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors show antitumor activity in prostate cancer. Two PARP inhibitors are FDA-approved for metastatic castrate-resistant prostate cancer, with more in clinical trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic castrate-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
- DNA repair defects are increasingly recognized as actionable targets in mCRPC.
Discussion:
- Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated promising antitumor activity in mCRPC.
- The efficacy of PARP inhibitors is linked to specific DNA repair gene alterations.
Key Insights:
- Olaparib and rucaparib are US Food and Drug Administration (FDA)-approved for mCRPC with select DNA repair defects.
- Ongoing clinical trials are evaluating talazoparib, veliparib, and niraparib in prostate cancer.
Outlook:
- Further advancements in PARP inhibitor therapy are anticipated for prostate cancer treatment.
- Personalized medicine approaches targeting DNA repair pathways will likely expand.
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
Overview of DNA Repair
Chemically...
Overview of DNA Repair
Long-patch Base Excision Repair
DNA Damage can Stall the Cell Cycle

